Account Login/Registration

Access KamloopsBCNow using your Facebook account, or by entering your information below.


Facebook


OR


Register

Privacy Policy

Acetaminophen product recalled due to labelling error that could lead to overdose or death

Health Canada has issued a recall for two lots of Novo−Gesic Forte Acetaminophen tablets distributed by Teva Canada because of a labelling error that could result in a person exceeding the maximum daily dosage for acetaminophen.

The 500 mg tablets were sold in packages containing 1,000 and 100 caplets, and were distributed in Canada starting Aug. 3, 2021.

The affected bottles have an expiration date of June 2023, with the lot numbers 35364729A and 35217483A.

The label on the bottle of affected products incorrectly states "do not take more than 4,000 mg (12 tablets) in 24 hours."

However, the correct number of tablets should be eight.

<who> Photo credit: Health Canada

Health Canada says consumers who follow the incorrect directions could ingest doses of acetaminophen ranging from 4,500 to 6,000 mg in 24 hours and experience symptoms of acetaminophen overdose.

Signs of acetaminophen overdose include nausea, vomiting, lethargy, sweating, loss of appetite and pain in the upper part of the abdomen or stomach.

Abdominal pain may be the first sign of liver damage, which can result in liver failure or death.

To date, Teva Canada Limited has not received any reports of adverse events related to the lots being recalled.

Customers are being told to stop using the products, and to contact their local poison control centre or emergency health care services immediately if they think they have taken too much acetaminophen.



Send your comments, news tips, typos, letter to the editor, photos and videos to [email protected].




weather-icon
Fri
23℃

weather-icon
Sat
26℃

weather-icon
Sun
29℃

weather-icon
Mon
32℃

weather-icon
Tue
33℃

weather-icon
Wed
32℃
current feed webcam icon

Top Stories

Follow Us

Follow us on Instagram Follow us on Twitter Like us on Facebook Follow us on Linkedin
Follow Our Newsletter
Privacy Policy